Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov;19(2):69-72.
doi: 10.17925/EE.2023.19.2.13. Epub 2023 Jun 15.

Fezolinetant: A Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause

Barbara DePree  1
Affiliations
Review

Fezolinetant: A Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause

Barbara DePree. touchREV Endocrinol. 2023 Nov.

Abstract

The most common symptom of menopause is vasomotor symptoms (VMS), which occur in more than 80% of postmenopausal women. Furthermore, VMS are the manifestation of menopause for which women most commonly seek treatment, namely, to address their impacted quality of life, including sleep, and work-and non-work-related productivity. VMS vary in frequency, intensity and duration. Hormone therapy (HT) has been our most effective treatment for VMS and has been approved for this indication by the United States Food and Drug Administration (FDA). Despite being a safe and effective treatment option, many patients and providers are hesitant to consider HT. Moreover, HT is contraindicated for some women. While many over-the-counter and non-HT options are available, we lack data on the efficacy and safety of most of these. This has left a void for women. Fezolinetant was recently approved by the FDA for the treatment of moderate-to-severe VMS. So far, clinical trials have shown positive results in terms of safety and efficacy. Fezolinetant is a non-hormonal, neurokinin 3 receptor antagonist that works in the hypothalamus at the thermoregulatory centre. Blocking the non-hormonal neurokinin 3 receptor antagonist modulates hot flashes and night sweats. As early as 4 weeks from initiating fezolinetant, women experienced a statistically significant reduction of both severity and frequency of VMS per day, resulting in an improved quality of life.

Keywords: Fezolinetant; menopause; neurokinin-3 receptor antagonist; novel treatment option; sleep; vasomotor symptoms.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Barbara DePree is on an advisory council for Astellas.

Similar articles

See all similar articles

References

    1. statista. Resident population of the United States by sex and age as of July 1, 2021. 2021. Available at: www.statista.com/statistics/241488/population-of-the-us-by-sex-and-age/ (Date last accessed: 22 May 2023)
    1. ACOG practice bulletin. Management of menopausal symptoms. Available at: www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2014/... (Date last accessed: 9 June 2023)
    1. Centers for Disease Control and Prevention. Life expectancy in the U.S dropped for the second year in a row in 2021. Available at: www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220831.htm (Date last accessed: 9 June 2023)
    1. Kopenhager T, Guidozzi F. Working women and the menopause. Climacteric. 2015;18:372–5. doi: 10.3109/13697137.2015.1020483. - DOI - PubMed
    1. Kagan R, Shiozawa A, Epstein AJ, Espinosa R. Impact of sleep disturbances on employment and work productivity among midlife women in the US SWAN database: A brief report. Menopause. 2021;28:1176–80. doi: 10.1097/GME.0000000000001834. - DOI - PMC - PubMed

Grants and funding

Support: No funding was received in the publication of this article.

LinkOut - more resources